Hyphens Pharma Inked Exclusive Licensing Deal of Ustekinumab Biosimilar

The proposed Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody that targets interleukin-12 (“IL-12”) and interleukin-23 (“IL-23”) for the treatment of immune mediated disorders like plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Click here to read our media release for more details.

Go top